Press release, 25 January 2023 at 8:00 a.m. (EET)

Nightingale Health Plc (“Nightingale Health”), a technology company promoting preventative health with its proprietary disease risk detection platform, will establish a laboratory in the United Kingdom to expand its commercial activities.

Nightingale Health has already been working for years with many leading universities in the United Kingdom and the technology is being used by many landmark health initiatives, such as the UK Biobank, to profile their entire sample collections. By having its proprietary blood analysis technology locally available in the United Kingdom, Nightingale Health aims to expand its partnerships within the medical research industry, and also to make the technology available to the entire health ecosystem.

”With more than 1.5 million samples analyzed globally, our technology provides major opportunities for new research projects, since every sample run with Nightingale Health’s technology is measured in comparable absolute concentrations. This means that new discoveries can be contextualized and replicated for example in the UK Biobank, the world’s largest biomedical research experiment. Furthermore, since our platform has regulatory approval for diagnostic use, medical scientists and the health industry can replace routine clinical chemistry biomarkers with our technology and get an extensive metabolic biomarker profile at the same time. Together the unparalleled replication opportunities and the ability to replace routine clinical biomarkers unlocks the full potential of precision preventative health. We are very excited to bring the technology locally available to the United Kingdom”, says Teemu Suna, Founder and CEO of Nightingale Health.

To support its expansion strategy in the United Kingdom, Nightingale Health has also hired a team to work there, consisting of leading experts in medical research sales and disease risk prediction.

“We warmly welcome Haroon Allybacus, who has joined Nightingale Health’s UK team to lead our sales operations for research institutions in the UK. Mr. Allybacus has previously worked for Metabolon Inc. and Biocrates GmbH. and has more than a decade of experience in providing commercial solutions of advanced molecular assays in the medical research market. Mr. Allybacus will be building commercial solutions for our customers in the UK to bring the benefits of Nightingale Health’s locally available technology, and we are delighted to have him in the team”, Suna continues.

”We are also delighted to announce that Dr. Luke Jostins-Dean has joined Nightingale Health’s UK team. He will have a key role in the previously announced center of excellence for genomics analysis and in realizing the opportunities for world class science in the UK with Nightingale Health’s technology. Dr. Jostins-Dean is a Group Leader and Associate Professor at the Kennedy Institute of Rheumatology in Oxford, and brings distinguished expertise in developing advanced algorithms to use genomic and other biological data to predict disease risk and enable preventative healthcare”, says Jeffrey Barrett, Nightingale Health’s Chief Scientific Officer.

The new laboratory will be available to analyze samples for customers in 2023, at a time to be announced later.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.